Active Implantable Medical Devices Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

Active Implantable Medical Devices Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The active implantable medical devices market is projected to register a CAGR of 7.2% during the forecast period.

The COVID-19 pandemic has had a large impact on the creation and use of medical devices, as well as most aspects of healthcare. Patients with cardiac implantable electronic devices (CIED) declined scheduled follow-up appointments during the global COVID-19 pandemic due to the risk of infection. Remote monitoring is intended to optimize the clinical treatment of CIED patients, enhance their quality of life, and decrease access to emergency rooms and hospitals. As per an article titled “Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey” published in February 2022, in hospitals around the world, Cardiac implantable electronic device (CIED) procedure rates for known active COVID-19 disease ranged from 0 to 16.2 per 1000 patients. High rates of complications and mortality were observed in patients with active COVID-19 infection who had CIED implantation. Before performing CIED implantation in patients with active COVID-19, operators should weigh these risks. These abovementioned factors are expected to have a significant impact on the growth of the market growth during and after the post-pandemic.

Certain factors that are driving the market growth include the increasing burden of cardiovascular and neurological diseases and investments and funds to develop technologically advanced products. As per an article titled “The prevalence and predictors of cardiovascular diseases in Kherameh cohort study: a population-based study on 10,663 people in southern Iran” published in, the prevalence of Cardiovascular Disease (CVD) increased from 257 million in 1990 to 550 million in 2020. Evidence has also indicated the global prevalence of angina to be 0.73–14.4% in females and 0.76–15.1% amongst males. The market for implantable devices is expected to grow due to several factors, including an aging population, an increase in cardiovascular and neurological diseases, investments in developing technologically advanced products, expanded uses for neurostimulators, and favorable reimbursement conditions for ENT procedures in developed nations.

Furthermore, increasing chronic diseases coupled with the advancements in active implantable medical devices are projected to boost market growth. As per an article titled “Commentary on Chronic Disease Prevention in 2022” published in 2022, nearly 60% of adult Americans have at least one chronic disease. Chronic conditions like diabetes, cancer, and cardiovascular disease are the leading causes of death in the United States.

Product approvals and launches are expected to boost the market growth. For instance, in December 2021, LifeTech Scientific Corporation extended its agreements with Medtronic to further the strategic collaboration on the "HeartTone domestic pacemaker project" and to start the collaboration on domestically-made MRI-conditional pacemakers. Additional to that, in February 2021, Boston Scientific Corporation initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM Modular Therapy System. The mCRM system consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy: the EMBLEM MRI subcutaneous implantable defibrillator system and the empower modular pacing system (MPS), which is designed to be the one of the first leadless pacemaker capable of delivering both bradycardia pacing support and antitachycardia pacing (ATP).

However, rising demand for non-invasive procedures, issues related to implantable devices, and the high cost of the devices are anticipated to impede market growth.

Key Market TrendsImplantable Cardiac Pacemaker is Expected to Witness Healthy Growth Over the Forecast Period

The implantable cardiac pacemakers are of three major types, namely, single-chamber, dual-chamber, and biventricular pacemakers. The growth of the segment can be attributed to factors, such as reduced post-surgical complications and the presence of multiple leads to assure normal physiology of the heart.

According to an article titled “Heart-disease risk soars after COVID — even with a mild case” published in February 2022, for at least a year following diagnosis, even a minor case of COVID-19 can raise a person's risk of cardiovascular issues. Over the year following infection, people who had recovered from COVID-19 exhibited substantial increases in 20 cardiovascular issues. In the COVID-19 group, there were approximately 12 additional cases of heart failure per 1,000 study participants, or a 72% increase in risk. These factors are expected to accelerate the usage of implantable cardiac pacemakers and drive segmental growth in the market. As per an article titled “Pacemaker” published in May 2022, between 500,000 and 3 million Americans have pacemakers implanted. With age, the likelihood of pacemaker insertion drastically rises. In actuality, patients over the age of 65 receive more than 70% of all pacemaker implantations.

Various product launches are expected to accelerate the segmental growth in the market. for instnace, in June 2021, Medtronic Private Limited, India, announced the launch of Micra AV - a miniaturize ully self-contained pacemaker that delivers advanced pacing technology to atrioventriculor (AV) block patients by minimally invasive approach.

Thus, the above-mentioned factors and the increasing usage of implantable cardiac pacemakers is expected to drive segmental growth in the market.

North America Dominates the Market and Expected to do Same Over the Forecast Period

North America is expected to hold a significant share in the market and is expected to do the same in the forecast period.

The rising prevalence of cardiovascular diseases, high obesity rates, and favorable reimbursement environments are the primary factors that are driving the market growth. A few of the key market players in the country are developing novel products that are expected to promote the market in the region. For instance, in February 2020, Mexico joined the HEARTS initiative to strengthen primary healthcare for Cardiovascular Diseases. Promoted by the Pan American Health Organization/World Health Organization (PAHO/WHO), the initiative aims to improve the prevention and control of hypertension at the primary care level. Thus, owing to the abovementioned factors, the studied market in the country is expected to register significant growth over the forecast period.

According to the Centers for Disease Control and Prevention (CDC)’s article titled "Heart Disease Facts", updated in September 2020, heart disease is the leading cause of death in the United States. The same source also reports that every year, about 805,000 Americans have a heart attack. As per Centers for Disease Control and Prevention (CDC) statistics, more than three million people in the United States suffer from atrial fibrillation, which is the most common type of abnormal heart rhythm. Furthermore, the number is expected to quadruple by 2050, as the population ages. Therefore, the increasing burden of cardiovascular diseases is expected to accelerate the demand for the market in the region during the forecast period.

As per an article titled "Prevalence and treatment of neuropathic pain diagnoses among U.S. nursing home residents" published in July 2022, the prevalence of neuropathic pain was 14.6% in the United States. Thus, the high incidence of neuropathic pain is also one of the reasons expected to drive the market in the region. The rise in cases of failed back surgery syndrome (FBSS), patients with neuropathic pain, and efforts to manage chronic neuropathic pain with methods other than chronic opioid therapy have all contributed to the emergence of neurostimulation in the country.

In February 2022, the United States Food and Drug Administration (FDA) approved Abbott’s CardioMEMS HF System to support the care of more people living with heart failure. Such product approvals are also expected to drive market growth in the region

Therefore, the above-mentioned factors are expected to drive market growth in the region during the forecast period.

Competitive Landscape

The global active implantable medical devices market is moderately competitive and consists of a few major players. Companies like Abbott Laboratories, Biotronik Se & Co., Kg, Boston Scientific Corporation, Cochlear Limited, Livanova PLC, Med-EL, Medtronic PLC, Nurotron Biotechnology Co. Ltd., Demant A/S, Sonova Holding AG, Smith & Nephew, Johnson & Johnson Services Inc., and Strykeramong others, hold the substantial market share in the Active Implantable Medical Devices market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.